Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2024-03-26EMA Authorised: Clopidogrel ratiopharm (clopidogrel (as hydrogen sulfate)) — Teva B.V.
European Medicines Agency authorises Clopidogrel ratiopharm (clopidogrel hydrogen sulfate) for multiple cardiovascular indications including…
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI [Phase 4]
Phase 4 trial evaluating pharmacodynamic and pharmacokinetic effects of switching from cangrelor to prasugrel in acute coronary syndrome pat…
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention [Phase 4]
A Phase 4 clinical trial evaluating genotype-guided selection of P2Y12 inhibitors after complex PCI in ACS patients with CYP2C19 polymorphis…
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI [Phase 2, Phase 3]
A phase 2/3 clinical trial update evaluating phentolamine for prevention of contrast-associated acute kidney injury after complex PCI.
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS) [NA]
Completed clinical trial comparing CT coronary angiography to traditional care in emergency department assessment of potential acute coronar…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2024-02-29EMA Authorised: Clopidogrel Teva (hydrogen sulphate) (clopidogrel (as hydrogen sulfate)) — Teva Pharma B.V.
EMA authorised Clopidogrel Teva (hydrogen sulphate) for multiple cardiovascular indications including acute coronary syndrome, myocardial in…
-
CLINICAL_TRIALS trial_result · 2024-02-23Clinical Trial Update: Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES [Phase 4]
Phase 4 clinical trial comparing personalized versus standard duration of dual antiplatelet therapy and comparing new-generation polymer-fre…
-
CLINICAL_TRIALS trial_result · 2024-02-23Clinical Trial Update: Platelet Aggregation in Diabetic Patients With Acute Coronary Syndrome Treated With Different Doses of Aspirin [Phase 4]
Phase 4 trial updating platelet aggregation in diabetic patients with acute coronary syndrome treated with different doses of aspirin.
-
CLINICAL_TRIALS trial_result · 2024-02-12Clinical Trial Update: Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome [Phase 2]
Phase 2 trial comparing 30 mg vs 75 mg aspirin dosing in elderly patients after acute coronary syndrome, investigating effects in myocardial…
-
CLINICAL_TRIALS trial_result · 2024-01-17Clinical Trial Update: NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI [Phase 4]
Phase 4 clinical trial evaluating NOAC therapy guided by PARIS risk score and D-dimer in patients with acute coronary syndrome after PCI.
-
EMA approval · 2023-12-19EMA Authorised: Clopidogrel Taw Pharma (previously Clopidogrel Mylan) (clopidogrel hydrochloride) — Taw Pharma (Ireland) Limited
EMA authorised a clopidogrel product (clopidogrel hydrochloride) by Taw Pharma (Ireland) Limited for peripheral vascular diseases, stroke, m…
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT) [Phase 4]
Phase 4 trial update evaluating colchicine for stability of coronary plaque in acute coronary syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2023-12-18Clinical Trial Update: Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome（MET STUDY） [Phase 4]
Phase 4 clinical trial update evaluating the effect of Yangxinshi Tablet on exercise tolerance in patients with chronic coronary syndrome.
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? [Phase 4]
Phase 4 clinical trial update investigating the optimal antithrombotic strategy for patients with atrial fibrillation undergoing PCI.
-
CLINICAL_TRIALS trial_result · 2023-12-07Clinical Trial Update: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients [Phase 4]
A Phase 4 trial evaluating low- and standard-dose ticagrelor after intervention in acute coronary syndrome patients undergoing coronary sten…
-
FDA approval · 2023-11-21FDA Approved: BIVALIRUDIN — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for bivalirudin from Dr. Reddy's Laboratories Limited, indicating an approved change to an exist…
-
CLINICAL_TRIALS trial_result · 2023-11-03Clinical Trial Update: Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes [Phase 4]
Phase 4 trial update comparing ticagrelor to clopidogrel in acute coronary syndrome completed.
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: Comparison Between Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients With Acute Coronary Syndrome [Phase 4]
Phase 4 trial comparing atorvastatin and rosuvastatin for reduction of inflammatory biomarkers in acute coronary syndrome.
-
CLINICAL_TRIALS trial_result · 2023-10-06Clinical Trial Update: A Study of Low Dose vs Standard Ticagrelor on Platelet Function After Intervention for Acute Coronary Syndrome in Senior Patients [Phase 4]
Phase 4 trial comparing low-dose versus standard ticagrelor on platelet function in senior patients after PCI for acute coronary syndrome.
-
CLINICAL_TRIALS trial_result · 2023-10-05Clinical Trial Update: Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome [Phase 4]
Phase 4 clinical trial evaluating evolocumab as an added lipid-lowering therapy and its impact on lipid core burden index in non-culprit vul…
-
CLINICAL_TRIALS trial_result · 2023-09-26Clinical Trial Update: The Effect of Colchicine on Inflammation in ACS Patients [Phase 3]
Phase 3 trial evaluating colchicine for inflammation in acute coronary syndrome, including STEMI, has completed.
-
CLINICAL_TRIALS trial_result · 2023-09-22Clinical Trial Update: Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients [Phase 4]
A Phase 4 clinical trial update investigating differential effects of dual antiplatelet and dual antithrombotic therapy on hemostasis in chr…
-
CLINICAL_TRIALS trial_result · 2023-09-08Clinical Trial Update: Ticin for the Treatment of Coronary Lesions With Drug Eluting Ballons [Phase 4]
A Phase 4 clinical trial in chronic coronary syndrome evaluating Ticin for treatment of coronary lesions using drug-eluting balloons is curr…
-
FDA approval · 2023-09-07FDA Approved: CLOPIDOGREL — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for clopidogrel bisulfate (generic clopidogrel) by Apotex Corp., under the ANDA, authorizing a modif…
-
FDA approval · 2023-08-28FDA Approved: PRASUGREL — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved the original application for prasugrel as a generic version (ANDA 213315) manufactured by Unichem Pharmaceuticals (USA), Inc. T…